elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q38270129-7185AD69-8C04-4C3D-8F28-AE1DEB2E6F5D
Q38270129-7185AD69-8C04-4C3D-8F28-AE1DEB2E6F5D
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38270129-7185AD69-8C04-4C3D-8F28-AE1DEB2E6F5D
The biology and clinical development of MEK inhibitors for cancer.
P2860
Q38270129-7185AD69-8C04-4C3D-8F28-AE1DEB2E6F5D
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38270129-7185AD69-8C04-4C3D-8F28-AE1DEB2E6F5D
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
f3bb3faed4097fd625a5746420361c6a05b1981d
P2860
Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.